IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis. (April 2022) - Huang, C.N.; Tsou, S.H.; Li, H.H.; Lin, S.C.; Lin, C.L.